Individualizing Prophylaxis in Hemophilia

Program Goals

Joint Bleeding and Progression of Joint Damage

Preventing Joint Bleeding in Hemophilia Prophylactic Factor Replacement Therapy

Prophylaxis Swedish Experience

Prophylaxis Swedish Experience (cont)

Joint Disease and Annual Joint Bleeding Rate

Orthopedic Outcome Study

Orthopedic Outcome Study (cont)

Joint Outcome Study Summary of Results

Canadian Dose-Escalation Study

Canadian Dose-Escalation Study Potential Effect of Subclinical Bleeding on Joint Status

Comparison of MRI, Orthopedic, and Radiologic Joint Scores in Young Boys With Hemophilia

Comparison of MRI, Orthopedic, and Radiologic Joint Scores in Young Boys With Hemophilia (cont)

When Should Prophylaxis Be Initiated?

Which Patients Should Be Receiving Prophylaxis?

Does Prophylaxis Put Patients at Risk for Inhibitors?

Which Factor Products Can Be Used for Prophylaxis?

Use of New Extended Half-life Factor VIII and Factor IX in Prophylaxis

How to Evaluate Whether Prophylaxis Is Working

Monitoring Patients Receiving Prophylaxis

What Is an Optimal Factor Level to Prevent Bleeding?

Joint Bleeding and Hemophilia Severity

Methods Used to Measure Patient Adherence to Prophylaxis

Adherence to Prophylaxis

Adherence to Prophylaxis in Severe Hemophilia Nurse Survey

On-demand and Prophylactic Treatment Across Age Groups in Severe Hemophilia A Nurse Survey

Patient-reported Reasons for Nonadherence

Consequences of Poor Adherence to Hemophilia Treatment

Summary

Abbreviation

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)